FDA Rejects Galderma's RelabotulinumtoxinA for Second Time

The aesthetic market for neuromodulators, primarily driven by botulinum toxin type A products, continues its steady expansion. Clinicians and patients alike seek formulations that offer predictable results, a rapid onset of action, and a sustained duration of effect. Galderma's relabotulinumtoxinA, a novel liquid formulation, entered development with the promise of addressing some of these desires, aiming to simplify preparation and potentially improve consistency compared to lyophilized products. The drug's journey to market has been fraught, however, culminating in a second Complete Response Letter from the US Food and Drug Administration. This latest rejection underscores persistent regulatory hurdles, specifically concerning manufacturing and quality control processes, rather than the clinical data itself.

RelabotulinumtoxinA is a highly purified botulinum toxin type A, developed as a ready-to-use liquid formulation. This eliminates the need for reconstitution, a step required for most currently available botulinum toxin products. The proposed indications included the temporary improvement of moderate to severe glabellar lines (frown lines) and lateral canthal lines (crow's feet). Galderma's New Drug Application (NDA) for relabotulinumtoxinA was supported by a comprehensive clinical program, including the READY-1 and READY-2 Phase III trials for glabellar lines, and the READY-3 trial for lateral canthal lines. These trials collectively enrolled over 1,900 participants across multiple sites, evaluating the drug's efficacy, safety, and duration of effect. The primary endpoint for efficacy in the glabellar line studies was the proportion of responders at Week 4, defined as a 2-point or greater improvement from baseline on both the investigator and patient Global Aesthetic Improvement Scale (GAIS).

Manufacturing Concerns Persist

The FDA's initial Complete Response Letter for relabotulinumtoxinA, issued in October 2023, cited deficiencies related to manufacturing processes. Galderma subsequently resubmitted the NDA, believing it had addressed the agency's concerns. But the second CRL, announced in June 2024, indicates that these issues remain unresolved. The agency has not raised concerns regarding the clinical safety or efficacy data generated from the extensive Phase III program. Instead, the focus remains squarely on the manufacturing facility and associated quality control systems, suggesting a systemic problem that requires significant remediation before the drug can be considered for approval.

In the READY-1 and READY-2 trials, relabotulinumtoxinA demonstrated robust efficacy for glabellar lines. In READY-1, a total of 691 patients were randomised to receive either 20U or 40U of relabotulinumtoxinA or placebo. At Week 4, 87% of patients receiving 20U and 95% of patients receiving 40U achieved the primary endpoint, compared to 1% for placebo (P<.001 for both doses vs. placebo). Similar results emerged from READY-2, which enrolled 670 patients. Here, 84% of patients in the 20U group and 94% in the 40U group met the primary endpoint at Week 4, versus 1% for placebo (P<.001 for both). The duration of effect, a key differentiator in the neuromodulator market, also appeared favorable. In READY-1, the median duration of effect for the 40U dose was 24 weeks, with some patients maintaining improvement for up to 36 weeks. The 20U dose showed a median duration of 16 weeks. These figures compare favorably to existing products, which typically offer 3-4 months of effect.

The READY-3 trial, which investigated relabotulinumtoxinA for lateral canthal lines, also reported positive outcomes. Patients treated with 20U of relabotulinumtoxinA achieved a 90% responder rate at Week 4, compared to 1% for placebo (P<.001). The median duration of effect for this indication was 20 weeks. Across all trials, the safety profile of relabotulinumtoxinA was consistent with other botulinum toxin products. The most common adverse events were injection site reactions, headache, and eyelid ptosis, all generally mild to moderate in severity and transient. No new or unexpected safety signals emerged from the large patient exposure.

But strong clinical data, however compelling, cannot overcome manufacturing deficiencies in the eyes of the FDA. The agency's stringent requirements for Good Manufacturing Practice (GMP) ensure product quality, consistency, and safety. A CRL focused on manufacturing typically means the FDA identified issues with facility controls, process validation, sterility assurance, or other aspects of production that could compromise the drug's integrity or potency. Until these issues are fully resolved and verified through re-inspection or additional documentation, the drug cannot proceed to approval. The specific nature of the deficiencies remains confidential between Galderma and the FDA, but the repeated rejection suggests a complex and perhaps deeply embedded problem within the production pipeline for relabotulinumtoxinA.

The repeated delays for relabotulinumtoxinA highlight the significant regulatory hurdles even well-established pharmaceutical companies face. Galderma, a major player in the dermatology space, has extensive experience navigating these processes. Still, the FDA's unwavering stance on manufacturing quality demonstrates its commitment to public safety over market expediency. The company has stated it will continue to work with the FDA to address the concerns. But the timeline for a potential resubmission and subsequent approval remains uncertain, leaving clinicians and patients waiting for a product that has shown clinical promise but cannot yet meet regulatory standards for production.